



1-21-03
PT20 Rec'd PCT/PC 16 JAN 2003

PATENT
Attorney Docket No. 218811
DHHS Ref. E-025-99

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Goldman et al.

Application No. 10/089,009

Filing Date: March 25, 2002

Group Art Unit: Unassigned

Examiner: Unassigned

For: INTERLEUKIN-2 RECEPTOR ASSOCIATED
POLYPEPTIDES

RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE


U.S. Patent and Trademark Office
Box SEQUENCE
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

In response to the Notification of Defective Response (copy enclosed) mailed on December 16, 2002, Applicants hereby submit a nucleotide/amino acid sequence listing in written form (paper copy) and in computer-readable form (diskette) in the above-identified patent application, and request that the sequence listing be entered into the application.

The undersigned hereby verifies that the contents of the written form and computer-readable form are identical, and that they do not introduce new matter into the patent application


Respectfully submitted,



Carol Larcher, Reg. No. 35,243
One of the Attorneys for Applicants
LEYDIG, VOIT & MAYER, LTD.
Two Prudential Plaza, Suite 4900
180 North Stetson
Chicago, Illinois 60601-6780
(312) 616-5600 (telephone)
(312) 616-5700 (facsimile)


Date: January 16, 2003

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this correspondence and the documents referred to as attached or enclosed therein are being deposited with the United States Postal Service on January 16, 2003, in an envelope as "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 CFR 1.10, Mailing Label Number 6L190837027 US addressed to: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202.


Printed Name of Person Making Deposit


Signature of Person Making Deposit



10 R356 2320

JAN 2003

E. Allen March

218811


UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box 901
 United States Patent and Trademark Office
 Washington, D.C. 20231
 www.uspto.gov

TRANSFERRED

U.S. APPLICATION NUMBER NO	FIRST NAMED APPLICANT	ATTY DOCKET NO
10/089,009	James R Davenport	NIH-05111

Hom Judith S H
 Medlen & Carroll
 101 Howard street Suite 350
 San Francisco, CA 94105



INTERNATIONAL APPLICATION NO	
PCT/US00/25963	
1A FILING DATE	PRIORITY DATE
09/21/2000	09/24/1999

CONFIRMATION NO. 5287
 371 FORMALITIES LETTER



OC000000009213238

Date Mailed: 12/16/2002

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fee
- Priority Document
- Assignee Statement
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Oath or Declaration
- Request for Immediate Examination

LEYDIG, VOT & MAYER
 RECEIVED

DEC 20 2002

PAT/TEM Due Date

1/16/03

Applicant's response filed 08/06/2002 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 06/12/2002 have not been completed.

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
 - APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an

LAH

AHF

amendment directing its entry into the specification.

- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase PatentIn Software, call (703) 306-2600
 - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

CHRISTINE S WASHINGTON

Telephone: (703) 305-3752

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/089,009	PCT/US00/25963	NIH-05111

FORM PCT/DO/EO/916 (371 Formalities Notice)